<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265967</url>
  </required_header>
  <id_info>
    <org_study_id>L_9917</org_study_id>
    <nct_id>NCT00265967</nct_id>
  </id_info>
  <brief_title>Irbesartan in Hypertension</brief_title>
  <official_title>Missed Dose Effect of Irbesartan in Hypertensive Patients and Cardiovascular Risk Profile Monitoring Under Irbesartan Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Study objectives:

        -  To demonstrate the effect of irbesartan on the regulation of diastolic blood pressure,
           in case of missing one dose after a period of administration for 6 to 8 weeks

        -  To evaluate the safety of irbesartan
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in 24 hours mean ambulatory blood pressure on the missing dose day. Frequency, severity, seriousness of adverse events emerging during the treatment , and their relation with the study drug.</measure>
    <time_frame>at the end of 6th months to 8th</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure measurements recorded in patients' diaries, and during visits.</measure>
    <time_frame>6-8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irbesartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Irbesartan 150-300 mg/d for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having an average value of ≥ 95 mmHg and ≤ 109 mmHg in diastolic blood pressure
             measurement or an average diastolic blood pressure value of ≥ 85 mmHg in 24-hours
             arterial blood pressure measurement,

          -  Received no treatment within the last 3 months.

        Exclusion Criteria:

          -  Premenopausal women having at least one of the following conditions,

               -  Not surgically sterile,

               -  Are nursing,

               -  Having childbearing potential and not using a reasonable contraception method or
                  not thinking to continue the method throughout the study. Reasonable
                  contraception methods are: intrauterine device, oral or implantable or injectable
                  contraception methods. No methods other than these are accepted.

          -  Patients routinely sleeping within the day since she/he works at nightshift and whose
             working hours continue in a time shift from midnight to 04:00 A.M.

          -  Patients with average systolic blood pressure = 180 mmHg in sitting position or
             average diastolic blood pressure is ≥110 mmHg in sitting position at baseline visit

          -  Having known or suspected secondary hypertension

          -  Having renal and/or hepatic failure together with the following laboratory criteria:

               -  Having elevated values of SGPT (ALT) or SGOT (ALT) (at least twice the upper
                  limit of normal range)

               -  Having serum creatinine levels of &gt; 2.3 mg/dL (or &gt; 203 μmol/L)

          -  With bilateral renal artery stenosis or single kidney and unilateral renal artery
             stenosis or those in post-renal transplantation or with single kidney,

          -  Having symptomatic sodium insufficiency, hypokalemia or hyperkalemia,

          -  With volume deficiency,

          -  With primary hyperaldosteronism,

          -  With biliary obstructive disorders,

          -  Having congestive heart failure (New York Heart Association (NYHA)-functional class
             CHF III-IV),

          -  With unstable angina pectoris occurring within 3 months before he or she signed the
             informed consent.

          -  With stroke occurring within 6 months before he or she signed the informed consent,

          -  With myocardial infarction or having cardiac surgery within three months before he or
             she signed the informed consent,

          -  Underwent PTCA (percutaneous transluminal coronary revascularization) within three
             months before he or she signed the informed consent,

          -  Having continuous tachycardia, atrial fibrillation, atrial flutter or other clinical
             arrythmias defined by the investigator

          -  With hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically related
             aortic or mitral valve stenosis,

          -  With insulin-dependant diabetes mellitus whose blood sugar regulation could not be
             controlled within the last 3 months after a HbA1C measurement in which it is equal to
             10%.

          -  With a history of drug or alcohol addiction within the last 6 months before she or he
             signed the informed consent,

          -  Receiving a drug other than those defined in protocol for blood pressure regulation,

          -  Who have been participated in any investigational study within the prior month before
             she or he signed the informed consent

          -  With a known hypersensitivity against any drug which will be used.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edibe Taylan</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

